In addition, other studies found that STING agonists synergize with CAR-T cells, enhancing their ability to control tumor growth (58), and administration of the STING ligand cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) improved the antitumor responses in models of melanoma and colon cancer (59, 60). The gene discussed is STING1; the disease is colonic neoplasm.